Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

Cites (545)

Items 401–541 of 541

1. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
   Nadira Ruzehaji, C. Frantz, Matthieu Ponsoye, Jérôme Avouac, Sonia Pezet, Thomas Guilbert, Jean‐Michel Luccarini, Pierre Broqua, Jean‐Louis Junien, Yannick Allanore · 2016 · Annals of the Rheumatic Diseases
2. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo
   Catherine T Frenette, Giuseppe Morelli, Mitchell L. Shiffman, R. Todd Frederick, Raymond A. Rubin, Michael B. Fallon, Jason Tzuying Cheng, Matt C. Cave, Saira Aijaz Khaderi, Omar I. Massoud et al. · 2018 · Clinical Gastroenterology and Hepatology
3. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes
   Diana Barb, Fernando Bril, Srilaxmi Kalavalapalli, Kenneth J. Cusi · 2019 · The Journal of Clinical Endocrinology & Metabolism
4. Lean NAFLD: an Underrecognized Outlier
   Julia J. Wattacheril, Arun Jayant Sanyal · 2016 · Current Hepatology Reports
5. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?
   Jun Liong Chin, Michael Pavlides, Ahmad Moolla, John Denis Ryan · 2016 · Frontiers in Pharmacology
6. Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders
   Jonathan Hazlehurst, Jeremy Tomlinson · 2013 · European Journal of Endocrinology
7. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial
   Bril, Fernando, Portillo Sanchez, Paola, Lomonaco, Romina, Orsak, Beverly, Hecht, Joan, Tio, Fermin, Cusi, Kenneth · 2017 · The Journal of Clinical Endocrinology & Metabolism
8. PYY plays a key role in the resolution of diabetes following bariatric surgery in humans
   Claudia Guida, Sam D. Stephen, Michael Watson, Niall J. Dempster, Pierre Larraufie, Thomas Marjot, Tamsin N. Cargill, Lisa Rickers, Michael Pavlides, Jeremy Tomlinson et al. · 2019 · EBioMedicine
9. Dorothy Hodgkin Lecture 2012* Non‐alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management
   Christopher D. Byrne · 2012 · Diabetic Medicine
10. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
    Peter H. Jones, Harold Edward Bays, Umesh Chaudhari, Robert C. Pordy, Christelle Lorenzato, Kathryn Miller, Jennifer G. Robinson · 2016 · The American Journal of Cardiology
11. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
    Gastaldelli, Amalia, Gaggini, Melania, Daniele, Giuseppe, Ciociaro, Demetrio, Cersosimo, Eugenio, Tripathy, Devjit, Triplitt, Curtis, Fox, Peter, Musi, Nicolas, DeFronzo, Ralph et al. · 2016 · Hepatology
12. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
    Mona Munteanu, DINA G. TINIAKOS, Quentin Mark Anstee, Frédéric Charlotte, Giulio Marchesini, Elisabetta Bugianesi, Michael A Trauner, Manuel Romero‐Gómez, Claudia Pinto Marques Souza de Oliveira, Christopher Paul Day et al. · 2016 · Alimentary Pharmacology & Therapeutics
13. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan
    Dominique M. Roulot, Françoise Roudot‐Thoraval, G. Nkontchou, Narcisse Kouacou, Jean‐Luc Costes, Ghassan Elourimi, Hervé Le Clésiau, Marianne Ziol, Michel Beaugrand · 2017 · Liver International
14. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial
    Abigail Fraser, R Abel, Debbie A. Lawlor, Drora Fraser, Asher Elhayany · 2008 · Diabetologia
15. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
    Salomon Marcello Stemmer, Ofer Benjaminov, Gal Medalia, N.B. Ciuraru, Michael H. Silverman, Sara Bar‐Yehuda, Sari Fishman, Zivit Harpaz, Motti Farbstein, Shira Cohen et al. · 2012 · The Oncologist
16. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis
    Shanshan Jin, Suwen Jiang, Airong Hu · 2018 · Sleep And Breathing
17. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study
    Claudia Della Corte, Antonella Mosca, Andrea Vania, Arianna Alterio, Salvatore Iasevoli, Valério Nobili · 2017 · Nutrition
18. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease
    Teng‐Yu Lee, Jaw‐Ching Wu, Shi‐Hang Yu, Jaw‐Town Lin, Ming‐Shiang Wu, Chun‐Ying Wu · 2017 · International Journal of Cancer
19. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation
    Giacomo Germani, Marie A. Laryea, Laura Rubbia‐Brandt, Hiroto Egawa, Patrizia Burra, John O’Grady, Kymberly D. S. Watt · 2018 · Transplantation
20. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity
    Guangrong Dai, Pengfei Liu, Xiaomei Li, Xiaoyan Zhou, Shuixiang He · 2019 · Medicine
21. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
    Seko, Yuya, Sumida, Yoshio, Tanaka, Saiyu, Mori, Kojiroh, Taketani, Hiroyoshi, Ishiba, Hiroshi, Hara, Tasuku, Okajima, Akira, Umemura, Atsushi, Nishikawa, Taichiro et al. · 2017 · Hepatology Research
22. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a <i>post hoc</i> analysis of the <scp>AWARD</scp> programme
    Cusi, K., Sattar, N., García‐Pérez, L.‐E., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., Haupt, A. · 2018 · Diabetic Medicine
23. Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
    Elena Pavlova Filipova, Katya Hristova Uzunova, Krassimir Kalinov, Toni Yonkov Vekov · 2017 · Diabetes Therapy
24. Dietary Patterns Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Chinese Adults
    Chaoqun Yang, Long Shu, Shuai Wang, Jia-Jia Wang, Yu Zhou, Yu-Jie Xuan, Sufang Wang · 2015 · Nutrients
25. Role of Fatty Acids in the Pathogenesis of Obesity and Fatty Liver: Impact of Bariatric Surgery
    Elizabeth Verna, P. Berk · 2008 · Seminars in liver disease (Print)
26. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
    Giovanni Targher, Giulio Marchesini, Christopher D. Byrne · 2016 · Diabetes & Metabolism
27. Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib
    Zobair M. Younossi, Maria Stepanova, Eric Lawitz, Michael Charlton, Rohit Seth Loomba, Robert P. Myers, Mani G. Subramanian, John G. McHutchison, Zachary D Goodman · 2018 · Liver International
28. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity
    Ylse Gutiérrez-Grobe, Norberto Carlos Chávez-Tapia, Vicente Sánchez-Valle, Juan G. Gavilanes-Espinar, Guadalupe Ponciano‐Rodríguez, Misael Uribe, Nahúm Méndez‐Sánchez · 2012 · Annals of Hepatology
29. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis
    Romina Lomonaco, Carolina Ortiz‐Lopez, Beverly Orsak, Joan Finch, Amy Webb, Fernando Bril, Christopher Louden, Fermin O. Tio, Kenneth J. Cusi · 2011 · Hepatology
30. Toll-Like Receptors in Liver Disease
    Jan Petrášek, Tímea Csák, Gyöngyi Szabó · 2012 · Advances in clinical chemistry
31. Vitamin E Supplements and Risk of Prostate Cancer in U.S. Men
    Carmen Rodríguez, Eric J. Jacobs, Alison M. Mondul, Eugenia E. Calle, Marjorie L. McCullough, Michael J. Thun · 2004 · Cancer Epidemiology Biomarkers & Prevention
32. Improvement of the Metabolic Syndrome and of Non-alcoholic Liver Steatosis upon Treatment of Hypogonadal Elderly Men with Parenteral Testosterone Undecanoate
    Haider, A., Gooren, L. J. G., Padungtod, P., Saad, F. · 2009 · Experimental and Clinical Endocrinology &amp; Diabetes
33. Efficacy of pitavastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study
    Hideyuki Hyogo, Tadashi Ikegami, Katsutoshi Tokushige, Etsuko Hashimoto, Kazuo Inui, Yasushi Matsuzaki, Hironori Tokumo, Fumiaki Hino, Susumu Tazuma · 2011 · Hepatology Research
34. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes
    Fabio Nascimbeni, Elisa Pellegrini, Simonetta Lugari, Alberto Mondelli, S. Bursi, Giovanna Onfiani, Francesca Carubbi, Amedeo Lonardo · 2019 · Atherosclerosis
35. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
    He, Yan‐Ling, Haynes, William, Meyers, Charles D., Amer, Ahmed, Zhang, Yiming, Mahling, Ping, Mendonza, Anisha E., Ma, Shenglin, Chutkow, William, Bachman, Eric · 2019 · Diabetes, Obesity and Metabolism
36. NONALCOHOLIC FATTY LIVER DISEASE IN MENOPAUSAL WOMEN
    Gesira Soares de Assis Florentino, Helma Pinchemel Cotrim, Consuelo P. Vilar, André Vinícius de Assis Florentino, Geruza Maria Almeida GUIMARAES, Victorino Spinelli Toscano Barreto · 2013 · Arquivos de Gastroenterologia
37. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis
    Yun-Hua Li, Luhua Yang, Kaihui Sha, Tonggang Liu, Liguo Zhang, Xianxian Liu · 2015 · World Journal of Gastroenterology
38. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
    Jérôme Avouac, Irena Konstantinova, Christophe Guignabert, Sonia Pezet, Jérémy Sadoine, Thomas Guilbert, Anne Cauvet, Ly Tu, Jean‐Michel Luccarini, Jean‐Louis Junien et al. · 2017 · Annals of the Rheumatic Diseases
39. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
    Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida et al. · 2018 · Diabetes Metabolic Syndrome and Obesity
40. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?
    Oscar Chávez‐Talavera, Joel T. Haas, Guillaume Grzych, Anne Tailleux, Bart Staels · 2019 · Current Opinion in Lipidology
41. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
    Ahmad Moolla, Kenzo Motohashi, Thomas Marjot, Amelia Shard, Mark Andrew Ainsworth, Alastair McIntosh Gray, Rury R. Holman, Michael Pavlides, John Denis Ryan, Jeremy Tomlinson et al. · 2019 · Frontline Gastroenterology
42. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis
    Philip Noel Newsome, Michael Allison, Paul A. Andrews, Georg M. Auzinger, Christopher Paul Day, James Ferguson, Peter A. Henriksen, Stefan G. Hübscher, H Manley, Patrick James McKiernan et al. · 2012 · Gut
43. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
    Takamasa Ohki, Akihiro Isogawa, Nobuo Toda, Kazumi Tagawa · 2016 · Clinical Drug Investigation
44. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
    Mary Eugenia Rinella, James F. Trotter, Manal F. Abdelmalek, Angelo H. Paredes, Margery A. Connelly, Mark J Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, Stephen A. Harrison · 2018 · Journal of Hepatology
45. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents
    Valério Nobili, Daniela Liccardo, Giorgio Bedogni, Guglielmo Salvatori, Daniela Gnani, Iliana Bersani, Anna Alisi, Luca V. C. Valenti, Massimiliano Raponi · 2014 · Genes & Nutrition
46. Characteristics of non‐obese non‐alcoholic fatty liver disease: Effect of genetic and environmental factors
    Yasushi Honda, Masato Yoneda, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Hironori Mawatari, Koji Fujita, Hideyuki Hyogo, Takato Ueno et al. · 2016 · Hepatology Research
47. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
    Amanda C. Cheung, Brent A. Neuschwander‐Tetri, David Erwin Kleiner, Elmer Schabel, Mary Eugenia Rinella, Stephen A. Harrison, Vlad Ratziu, Arun Jayant Sanyal, Rohit Seth Loomba, Sophie Jeannin Megnien et al. · 2019 · Hepatology
48. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
    Anna Vanderheiden, Lindsay Harrison, Jeremy T. Warshauer, BEVERLEY A. ADAMS-HUET, Xilong Li, Qing Yuan, Keith Hulsey, Ivan E. Dimitrov, Takeshi Yokoo, Adam W. Jaster et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism
49. Hepatic fatty acid partitioning
    Leanne Hodson, Keith N. Frayn · 2011 · Current Opinion in Lipidology
50. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)
    Ki Hoon Han, Seung‐Woon Rha, Hyun‐Jae Kang, Jang‐Whan Bae, Byoung‐Joo Choi, So‐Yeon Choi, Hyeon‐Cheol Gwon, Jang‐Ho Bae, Bum‐Kee Hong, Donghoon Choi et al. · 2012 · Journal of clinical lipidology
51. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice
    Hitoshi Matsumoto · 2006 · World Journal of Gastroenterology
52. Collagen proportionate area is an independent predictor of long‐term outcome in patients with non‐alcoholic fatty liver disease
    Elena Buzzetti, Andrew Rennie Hall, Mattias Ekstedt, Roberta Manuguerra, Marta Guerrero Misas, Claudia Covelli, Gioacchino Leandro, Tu Vinh Luong, Stergios Kechagias, Emanuel K. Manesis et al. · 2019 · Alimentary Pharmacology & Therapeutics
53. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
    Tatjána Ábel, János Fehér, Elek Dinya, Mohamed Gamal El‐Din, Attila D Kovács · 2009 · PubMed
54. Clinical and metabolic effects associated with weight changes and obeticholic acid in non‐alcoholic steatohepatitis
    Bilal Hameed, Norah A. Terrault, Ryan M. Gill, Rohit Seth Loomba, Naga Chalasani, Jay H. Hoofnagle, Mark L. Van Natta, for the NASH CRN · 2018 · Alimentary Pharmacology & Therapeutics
55. AASLD position paper: Liver biopsy
    Don C. Rockey, Stephen Hugh Caldwell, Zachary D Goodman, Rendon C. Nelson, Alastair D. Smith · 2008 · Hepatology
56. MEDITERRANEAN DIET IS ASSOCIATED WITH LIVER HISTOLOGY IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE.
    R. Aller, Olatz Izaola, Beatriz de la Fuente, Daniel Antonio de Luis · 2015 · PubMed
57. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
    Shahinul Alam, Jhumur Ghosh, Golam Mustafa, Mohammad Amjad Kamal, Nooruddin Ahmad · 2018 · Hepatic Medicine Evidence and Research
58. Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
    Jonathan Hazlehurst, Andrei I. Oprescu, Nikolaos Nikolaou, Riccardo Di Guida, Annabel Grinbergs, Nigel P. Davies, Robert Flintham, Matthew James Armstrong, ANGELA E. R. TAYLOR, Beverly A. Hughes et al. · 2015 · The Journal of Clinical Endocrinology & Metabolism
59. Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer
    Koji Matsuo, Marc R. Gualtieri, Sigita S. Cahoon, Carrie E. Jung, Richard J. Paulson, Donna Shoupe, Laila I. Muderspach, Akihiko Wakatsuki, Jason Dennis Wright, Lynda D. Roman · 2015 · Menopause The Journal of The North American Menopause Society
60. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study
    Łukasz Tanajewski, Rebecca Harris, David J Harman, Guruprasad Padur Aithal, Tim R Card, Georgios Gkountouras, Vladislav Berdunov, Indra Neil Guha, Rachel Ann Elliott · 2017 · BMJ Open
61. Should patients with NAFLD/NASH Be surveyed for HCC?
    Reig, Maria, Gambato, Martina, Man, Nancy Kwan, Roberts, John P., Victor, David, Orci, Lorenzo A., Toso, Christian · 2019 · Transplantation
62. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery
    Roy Taylor, Ahmad H. Al-Mrabeh, Sviatlana V. Zhyzhneuskaya, Carl A. Peters, Alison C. Barnes, Benjamin S. Aribisala, Kieren G. Hollingsworth, John Cummings Mathers, Naveed A. Sattar, Michael E. J. Lean · 2018 · Cell Metabolism
63. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study
    Joanne R Morling, Jonathan Andrew Fallowfield, Indra Neil Guha, Lisa D. Nee, Stephen Glancy, Rachel M. Williamson, Christine M. Robertson, Mark W. J. Strachan, Jackie F. Price · 2013 · Journal of Hepatology
64. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non‐alcoholic steatohepatitis
    Matthew James Armstrong, Jonathan Hazlehurst, Diana Hull, Kaiwen Guo, Sarah Borrows, Jinglei Yu, Stephen C. L. Gough, Philip Noel Newsome, Jeremy Tomlinson · 2014 · Diabetes Obesity and Metabolism
65. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis
    Jianhua Shen, Yiling Li, Dan Li, Ningning Wang, Lei Jing, Yu‐Hong Huang · 2014 · Journal of Lipid Research
66. Independent Predictors of Steatohepatitis and Fibrosis in Asian Indian Patients with Non-Alcoholic Steatohepatitis
    Deepak Kumar Singh, Puja Sakhuja, Veena Malhotra, Ranjana Gondal, Shiv Kumar Sarin · 2007 · Digestive Diseases and Sciences
67. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus
    Young, Lawrence H., Viscoli, Catherine M., Curtis, Jeptha P., Inzucchi, Silvio E., Schwartz, Gregory G., Lovejoy, Anne M., Furie, Karen L., Gorman, Mark J., Conwit, Robin, Abbott, J. Dawn et al. · 2017 · Circulation
68. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.
    Takayuki Fukuhara, Hideyuki Hyogo, Hidenori Ochi, Hatsue Fujino, Hiromi Kan, Noriaki Naeshiro, Yohji Honda, Daisuke Miyaki, Tomokazu Kawaoka, Masataka Tsuge et al. · 2014 · PubMed
69. Transgenic expression of human neutrophil peptide‐1 enhances hepatic fibrosis in mice fed a choline‐deficient, L‐amino acid–defined diet
    Rie Ibusuki, Hirofumi Uto, Shiho Arima, Seiichi Mawatari, Yoshiko Setoguchi, Yuji Iwashita, Shinichi Hashimoto, Takuro Maeda, Shiro Tanoue, Shuji Kanmura et al. · 2013 · Liver International
70. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012
    Shuncong Wang, Huanhuan Sun, Zhinan Xie, Jie Li, Guobin Hong, Dan Li, Saradhi Mallampati, Xiuling Zhou, Cuiling Zhou, Hongyu Zhang et al. · 2016 · Oncotarget
71. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross‐sectional study using transient elastography
    D. J. Harman, Stephen D. Ryder, Martin Wynn James, Emilie Wilkes, Tim R Card, Guruprasad Padur Aithal, Indra Neil Guha · 2017 · Alimentary Pharmacology & Therapeutics
72. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease
    Elliot B. Tapper, Katherine Maragaret Krajewski, Michelle Lai, Tracy L. Challies, R. Kane, Nezam H. Afdhal, Daryl Lau · 2014 · Gastroenterology report
73. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease
    Raika Jamali, Mohsen Razavizade, Abbas Arj, Mohammad Hossein Aarabi · 2016 · World Journal of Gastroenterology
74. Effects of lixisenatide on elevated liver transaminases: Systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
    Gluud, Lise L, Knop, Filip K, Vilsbøll, Tina · 2014 · BMJ Open
75. Altered gut–liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver
    Valério Nobili, Anna Alisi, Renato Cutrera, Guido Carpino, Cristiano De Stefanis, Valentina Doria, Rita De Vito, Salvatore Cucchiara, Eugenio Gaudio, Giovanni Musso · 2015 · Thorax
76. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns
    Daniel Seung Kim, Anne U. Jackson, Yatong K. Li, Heather M. Stringham, Johanna Kuusisto, Antti J. Kangas, Pasi Soininen, Mika Ala‐Korpela, Charles Burant, Veikko V Salomaa et al. · 2017 · Journal of Lipid Research
77. Dietary patterns and non-alcoholic fatty liver disease in a Greek case–control study
    Ioanna Panagiota Kalafati, Dimitra Borsa, Maria Dimitriou, Konstantinos Revenas, Alexander D. Kokkinos, George V. Dedoussis · 2018 · Nutrition
78. GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH
    Zobair M. Younossi, Vlad Ratziu, Rohit Seth Loomba, Mary Eugenia Rinella, Quentin Mark Anstee, Zachary D Goodman, Pierre Bédossa, Andreas Geier, Susanne Beckebaum, Philip Noel Newsome et al. · 2019 · Journal of Hepatology
79. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials
    Ingrid Jullian‐Desayes, Renaud Tamisier, Jean‐Pierre Zarski, Judith Aron‐Wisnewsky, Sandrine H. Launois, Candice Trocmé, Patrick A. Levy, Marie Joyeux‐Faure, Jean‐Louis Pépin · 2015 · Respirology
80. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management
    Matthew James Armstrong, Jonathan Hazlehurst, Richard Parker, Elena Koushiappi, Jake Peter Mann, Sheeba Khan, Angela Philips, Liz Chandler, Jill L. Johnson, Maria Round et al. · 2013 · QJM
81. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society
    M. Soresi, D. Noto, A. Cefalù, S. Martini, G. Vigna, M. Fonda, E. Manzato, L. Cattin, R. Fellin, M. Averna et al. · 2013 · Acta Diabetologica
82. Neglected features of lifestyle: Their relevance in non-alcoholic fatty liver disease
    Francesca Maria Trovato, Giuseppe Fabio Martines, Daniela Brischetto, Guglielmo M. Trovato, Daniela Catalano · 2016 · World Journal of Hepatology
83. Lower Fructose Intake May Help Protect Against Development of Nonalcoholic Fatty Liver in Adolescents With Obesity
    Therese A. O’Sullivan, Wendy Hazel Oddy, Alexandra Bremner, Jill L. Sherriff, Oyekoya Taiwo Ayonrinde, John Kevin Olynyk, Lawrence Joseph Beilin, Trevor Anthony Mori, Leon Anton Adams · 2013 · Journal of Pediatric Gastroenterology and Nutrition
84. Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet
    Katherine J. P. Schwenger, Sandra Elisabeth Fischer, Timothy D. Jackson, Allan Okrainec, Johane P. Allard · 2017 · Obesity Surgery
85. Prevalence of nonalcoholic fatty liver disease in an adult population in a rural community of Haryana, India
    Anindo Majumdar, Puneet Misra, Sanjay Sharma, Shashi Kant, Anand Krishnan, ChandrakantS Pandav · 2016 · Indian Journal of Public Health
86. Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study
    Jeremy Cobbold, Stephen R. Atkinson, Julian Roberto Marchesi, Ann Smith, Sann N. Wai, Julie Stove, Fariba Shojaee‐Moradie, Nicola Jackson, Anne Margot Umpleby, Julie A. Fitzpatrick et al. · 2017 · Hepatology Research
87. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes
    HARPREET SINGH BAJAJ, Ruth E. Brown, L. Bhullar, N. Sohi, S. Kalra, Ronnie Aronson · 2018 · Diabetes & Metabolism
88. Ethnicity and the diagnosis gap in liver disease: a population-based study
    William Alazawi, Rohini Mathur, Kushala W. M. Abeysekera, Sally Hull, Kambiz Boomla, John P Robson, Graham R. Foster · 2014 · British Journal of General Practice
89. Nutritional Profile and Dietary Patterns of Lebanese Non-Alcoholic Fatty Liver Disease Patients: A Case-Control Study
    Nicole Fakhoury-Sayegh, Hassan Younes, Gessica N. H. A. Heraoui, Raymond Sayegh · 2017 · Nutrients
90. The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia
    Xiangdong Wu, Keyang Chen, Kevin Jon Williams · 2012 · Current Opinion in Lipidology
91. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC
    Alexandra Shingina, Peter E. DeWitt, Jennifer L. Dodge, Scott W. Biggins, Jane Gralla, David Sprague, Kiran M. Bambha · 2018 · Transplantation
92. An observational study on the association between major dietary patterns and non-alcoholic fatty liver disease in Chinese adolescents
    Xiaonan Liu, Yan Peng, Shuhong Chen, Qingyun Sun · 2018 · Medicine
93. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease
    Malek Yaghoubi, Sattar Jafari, Behnam Sajedi, Sepehr Gohari, Samira Akbarieh, Amir Hossein Heydari, Maryam Jameshorani · 2017 · European Journal of Gastroenterology & Hepatology
94. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
    Fernando Bril, Paola Portillo-Sánchez, I‐Chia Liu, Srilaxmi Kalavalapalli, Kristin Dayton, Kenneth J. Cusi · 2017 · Diabetes Care
95. Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline
    Ramona Cioboată, Alice Elena Găman, Diana-Maria Trașcă, Anca Marilena Ungureanu, Anca Oana Docea, Paul Ioan Tomescu, Florin Liviu Gherghina, Andreea Letiția Arsene, Corin Badiu, Aristidis Michael Tsatsakis et al. · 2017 · Experimental and Therapeutic Medicine
96. Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area
    Nicola Veronese, Maria Notarnicola, Anna Maria Cisternino, Rosa Reddavide, Rosa Inguaggiato, Vito Guerra, Ornella Rotolo, Iris Zinzi, Gioacchino Leandro, Mario Correale et al. · 2018 · Nutrients
97. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population
    Matthieu Wargny, Pierre‐Henri Ducluzeau, Jean‐Michel Petit, Cédric Le May, Sarra Smati, Lucie Arnaud, Matthieu Pichelin, Benjamin Bouillet, Adrien Lannes, Odile Blanchet et al. · 2018 · Atherosclerosis
98. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
    Robin Daniel Abeles, Benjamin Harvey Mullish, Roberta Forlano, Torben Kimhofer, Maciej Adler, Alexandros T. Tzallas, Νικόλαος Γιαννακέας, Michael S. Yee, Jamil Mayet, Robert David Goldin et al. · 2019 · Alimentary Pharmacology & Therapeutics
99. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Do androgens play a role?
    Robert P. Kauffman, Teresa Ellen Baker, Vicki M. Baker, Michele Milburn Kauffman, V. Daniel Castracane · 2009 · Gynecological Endocrinology
100. Prevalence and severity of non‐alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital
     Thomas Marjot, Emilia Sbardella, Ahmad Moolla, Jonathan Hazlehurst, G. D. Tan, Mark Andrew Ainsworth, Jeremy Cobbold, Jeremy Tomlinson · 2017 · Diabetic Medicine
101. Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects
     Zongsheng Huang, Xianwen Guo, Guo Zhang, Liexin Liang, Bing Nong · 2019 · The International Journal of Biological Markers
102. Transient elastography in acute hepatitis: All that's stiff is not fibrosis
     Jeremy Cobbold, Simon David Taylor-Robinson · 2008 · Hepatology
103. Hypoxia inducible factor‐1α induction by tumour necrosis factor‐α, but not by toll‐like receptor agonists, modulates cellular respiration in cultured human hepatocytes
     Tomás Regueira, Philipp Moritz Lepper, Sebastián Brandt, Matthias Ochs, Madhusudanarao Vuda, Jukka A. Takala, Stephan Matthias Jakob, Siamak Djafarzadeh · 2009 · Liver International
104. The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
     Akihiko Takeda, Aya Irahara, Atsuko Nakano, Emi Takata, Yuko Koketsu, Kunie Kimata, Eri Senda, Hajime Yamada, Kazuhito Ichikawa, Takahiro Fujimori et al. · 2017 · Internal Medicine
105. Obeticholic acid in primary biliary cholangitis
     Vignan Manne, Kris V. Kowdley · 2019 · Current Opinion in Gastroenterology
106. NAFLD: a multisystem disease that requires a multidisciplinary approach
     Christopher J. Danford, Michelle Lai · 2019 · Frontline Gastroenterology
107. Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN/AKT pathway
     Pradeep Kumar, Reben Raeman, Daniel M. Chopyk, Tekla Smith, Kiran Verma, Yunshan Liu, Frank A. Anania · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
108. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
     Stephen A. Harrison, Sam Moussa, Mustafa Rifaat Bashir, Naim Alkhouri, J. Frias, Seth J. Baum, Brent A. Tetri, M. Bansal, Rebecca A. Taub · 2018 · Journal of Hepatology
109. Continuous Positive Airway Pressure Therapy on Nonalcoholic Fatty Liver Disease in Patients With Obstructive Sleep Apnea
     Donghee Kim, Aijaz Ahmed, Clete A. Kushida · 2018 · Journal of Clinical Sleep Medicine
110. Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
     Gonzalo Labarca T., Rodrigo Cruz, Jorge Jorquera A · 2018 · Journal of Clinical Sleep Medicine
111. CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans
     Robert Bergholm, Ksenia Sevastianova, A Santos, Anna Kotronen, M Urjansson, Antti Hakkarainen, Jesper Lundbom, Mirja Tiikkainen, A Rissanen, Nina M I Lundbom et al. · 2012 · International Journal of Obesity
112. Mutant PNPLA3 I148M protein as pharmacological target for liver disease
     Luca V. C. Valenti, Paola Dongiovanni · 2017 · Hepatology
113. Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience
     Jeremy Cobbold, Sarrah Raveendran, Christopher M Peake, Quentin Mark Anstee, Michael S. Yee, Mark R. Thursz · 2013 · Frontline Gastroenterology
114. Cardiovascular disease outcomes related to early stage renal impairment after liver transplantation
     VanWagner, Lisa B., Montag, Samantha, Zhao, Lihui, Allen, Norrina B., Lloyd-Jones, Donald M., Das, Arighno, Skaro, Anton I., Hohmann, Samuel, Friedewald, John J., Levitsky, Josh · 2018 · Transplantation
115. JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study
     Annette M. Diehl, Stephen A. Harrison, Stephen Hugh Caldwell, Mary Eugenia Rinella, Angelo H. Paredes, Cynthia A. Moylan, C. Guy, M. Bashir, Y. Wang, L. Miller et al. · 2018 · Journal of Hepatology
116. Cardiorespiratory Fitness and Risk of Fatty Liver
     Kristiina S. Pälve, Katja Pahkala, Emmi Suomela, Heikki Aatola, Janne Hulkkonen, Markus Juonala, Terho J. Lehtimäki, Tapani Rönnemaa, Jorma S.A. Viikari, Mika A. P. Kähönen et al. · 2017 · Medicine & Science in Sports & Exercise
117. Nonalcoholic steatohepatitis in nonobese patients
     Kenneth J. Cusi · 2016 · Hepatology
118. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?
     Charlotte Green, Thomas Marjot, Jeremy Tomlinson, Leanne Hodson · 2018 · Diabetes Obesity and Metabolism
119. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease
     Murat Sünbül, Tarık Kıvrak, Erdal Durmuş, Hakan Akın, Yücel Aydın, Rabia Ergelen, Yusuf Nadir Yilmaz, Mehmet Ali Ağırbaşlı · 2015 · Cardiovascular Therapeutics
120. Cryptogenic cirrhosis: Current knowledge and future directions
     Alex Mercado‐Irizarry, Esther A. Torres · 2016 · Clinical Liver Disease
121. Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis
     Marianne Rebecca Spalinger, Kirstin Atrott, Katharina Baebler, Marlene Schwarzfischer, Hassan Melhem, Dan R Peres, Gadi Lalazar, Gerhard Rogler, Michael M. Scharl, Isabelle M. Frey-Wagner · 2018 · Journal of Crohn s and Colitis
122. Non-alcoholic fatty liver disease prevalence and associated risk factors – A study from rural sector of Maharashtra
     Lavekar Anurag, Saoji Aniket, Jadhav Shalik, Lavekar Amarja, Raje Dhananjay, Jibhkate Sachin · 2015 · Tropical Gastroenterology
123. The role of NAFLD in cardiometabolic disease: an update
     Sarah A. Faasse, Hayley Braun, Miriam B. Vos · 2018 · F1000Research
124. Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease?
     Gesira Soares de Assis Florentino, Helma Pinchemel Cotrim, André Vinícius de Assis Florentino, Consuelo P. Vilar, Manoel Medeiros-Neto, Gérson Bragagnoli, Paulo Adriano Schwingel · 2012 · Annals of Hepatology
125. Comparison of Once-Daily Bedtime Administration of Famotidine and Ranitidine in the Short-Term Treatment of Duodenal Ulcer a Multicenter, Double-Blind, Controlled Study
     Giorgio Dobrilla, G. De Pretis, L. Piazzi, Anna Boero, E Camarri, M. Crespi, Giovanna Fontana, Gaetano Ideo, F. Manenti, Giorgio Marenco et al. · 1987 · Scandinavian Journal of Gastroenterology
126. A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
     Naga Chalasani, Guadelupe Garcia-Tsao, Z. Goodman, E.J. Lawitz, Manal F. Abdelmalek, Mary Eugenia Rinella, Mohamed Ryan, Mazen Noureddin, C. Jue, Maximilian Pyko et al. · 2018 · Journal of Hepatology
127. Gastric bypass specifically impairs liver parameters as compared with sleeve gastrectomy, independently of evolution of metabolic disorders
     Séverine Ledoux, Ouidad Sami, Daniela Calabrese, Maude Le Gall, Martin Flamant, Muriel Coupaye · 2018 · Surgery for Obesity and Related Diseases
128. Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history
     Martin C. S. Wong, Jessica Y. L. Ching, Victor C. W. Chan, Thomas Yuen Tung Lam, Arthur K.C. Luk, Sunny H. Wong, Siew C. Ng, Vincent Wai‐Sun Wong, Simon S.M. Ng, Justin C. Wu et al. · 2015 · International Journal of Cancer
129. Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients
     Kristina Blaslov, Karin Zibar, Tomislav Bulum, Lea Smircic Duvnjak · 2013 · Clinics and Research in Hepatology and Gastroenterology
130. Validity of a Cochrane Systematic Review and meta-analysis for determining the safety of vitamin E
     Christopher J. Oliver, Stephen P Myers · 2017 · BMC Complementary and Alternative Medicine
131. The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage
     Patrizia Burra, Marina Berenguer, Elizabeth Anne Pomfret · 2018 · Transplantation
132. WHO European Childhood Obesity Surveillance Initiative: overweight and obesity among 6-9-year-old children.: Report of the third round of data collection 2012-2013
     Angela Spinelli, Paola Nardone · 2018
133. Addressing Western dietary pattern in obesity and NAFLD
     Francesca Maria Trovato, Giuseppe Fabio Martines, Daniela Catalano · 2018 · Nutrire
134. Preclinical and first-in human development of SGM-1019, a first-in-class novel small molecule modulator of inflammasome activity for the treatment of nonalcoholic steatohepatitis (NASH)
     Karim Dabbagh, G. Steven Dodson, L. Yamamoto, Bernat Baeza-Raja, Andrew Goodyear · 2018 · Journal of Hepatology
135. Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies
     Stuart McPherson, Raluca Pais, Luca V. C. Valenti, Jörn Markus Schattenberg, Jean‐François Dufour, Emmanuel A. Tsochatzis, Sven Francque, Timothy Hardy, M. Boyle, D. Tiniakos et al. · 2017 · Journal of Hepatology
136. The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4 weeks of treatment, an interim analysis of ongoing clinical trial, MN-001-NATG-201
     Kae Matsuda, J. Gutierrez, TAREK HASSANEIN, Yoshihiro IWAKI · 2018 · Journal of Hepatology
137. PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients
     Rohit Seth Loomba, Erin S. Morgan, Maple M. Fung, Lynnetta M. Watts, Richard S. Geary, Sanjay Bhanot · 2019 · Journal of Hepatology
138. The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016
     Sarah Ann Townsend, Philip Noel Newsome · 2017 · Digestive Diseases
139. Solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study
     Robert L. Dobbins, P. Gholam, S. Ertel, N. Furey, G.M. Baskaran, Z. Goodman, David Oldach, P Fernandes · 2017 · Journal of Hepatology
140. PS-111-Six month interim results of MSDC-0602 K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444)
     Stephen A. Harrison, Guy W. Neff, Julie Iwashita, Jules Lee, Donald J. Lazas, Kenneth J. Cusi, Arun Jayant Sanyal, Rohit Seth Loomba, Naim Alkhouri, Juan P. Frías et al. · 2019 · Journal of Hepatology
141. THU-309-Cardiovascular risk assessment and management improves outcomes in a specialist multidisciplinary non-alcoholic fatty liver disease clinic
     Atul Goyale, Marta Guerrero Misas, Laura Iogna Prat, Davide Roccarina, Devaki R. Nair, Emmanuel A. Tsochatzis · 2019 · Journal of Hepatology